<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Benztropine (benzatropine): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Benztropine (benzatropine): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Benztropine (benzatropine): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9106" href="/d/html/9106.html" rel="external">see "Benztropine (benzatropine): Drug information"</a> and <a class="drug drug_patient" data-topicid="11249" href="/d/html/11249.html" rel="external">see "Benztropine (benzatropine): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F24519898"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cogentin [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866048"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Benztropine Omega;</li>
<li>PDP-Benztropine;</li>
<li>VPI-Benztropine</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1056791"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Anti-Parkinson's Agent</span>;</li>
<li>
<span class="list-set-name">Anticholinergic Agent</span>;</li>
<li>
<span class="list-set-name">Antidote, Drug-induced Dystonic Reactions</span></li></ul></div>
<div class="block dop drugH1Div" id="F140221"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="457dff11-b2d9-431a-93b8-e5b26917426c">Drug-induced extrapyramidal symptoms</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Drug-induced extrapyramidal symptoms (EPS):</b> Limited data available: <b>Note:</b> Prophylactic use is generally not recommended to prevent antipsychotic-associated EPS, especially for second-generation antipsychotics; consider individual preferences, history of EPS, and baseline risk factors for EPS, including antipsychotic receptor binding and adverse effect profile (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19955388','lexi-content-ref-23972700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19955388','lexi-content-ref-23972700'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;3 years and Adolescents: Oral, IM, IV: 0.02 to 0.05 mg/kg/dose 1 to 2 times daily has been used for treatment of EPS; usual adult dose range: 1 to 4 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4424791','lexi-content-ref-10411778','lexi-content-ref-7492048','lexi-content-ref-Nelson.1','lexi-content-ref-33813918','lexi-content-ref-Pendopharm.2','lexi-content-ref-11869410']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4424791','lexi-content-ref-10411778','lexi-content-ref-7492048','lexi-content-ref-Nelson.1','lexi-content-ref-33813918','lexi-content-ref-Pendopharm.2','lexi-content-ref-11869410'])">Ref</a></span>). The IV route should be reserved for situations when oral or IM are not appropriate. In clinical trials of pediatric patients ≥8 years with early-onset schizophrenia spectrum disorders (EOSS), benztropine 0.5 mg orally twice daily has been used to reduce the risk of development of anti-psychotic drug-induced EPS due to first-generation antipsychotics (ie, molindone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20494268','lexi-content-ref-17667476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20494268','lexi-content-ref-17667476'])">Ref</a></span>). Prophylactic benztropine is not recommended in patients treated with second-generation antipsychotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19955388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19955388'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51073641"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51073642"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F140216"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9106" href="/d/html/9106.html" rel="external">see "Benztropine (benzatropine): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="457dff11-b2d9-431a-93b8-e5b26917426c">Drug-induced extrapyramidal symptoms</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Drug-induced extrapyramidal symptoms</b>
<b> (eg, dystonia, parkinsonism):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Diphenhydramine is not recommended for the management of akathisia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute treatment:</b>
<b>IM, IV, Oral:</b>
<b>Note: </b>Parenteral administration is preferred for initial treatment of severe acute symptoms. Once severe symptoms have resolved, transition to oral treatment. Duration of therapy and prophylactic use should be based on severity of extrapyramidal symptoms (EPS) reaction, pharmacologic profile of the causative agent (eg, half-life, adverse effects), and patient risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9359953','lexi-content-ref-19955388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9359953','lexi-content-ref-19955388'])">Ref</a></span>). Some experts recommend attempting taper and discontinuation after several weeks to months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22651987']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22651987'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">General dosing recommendations: Initial: <b>IM, IV, Oral:</b> 1 to 2 mg 2 to 3 times daily; adjust dose based on response and tolerability in 0.5 mg increments at intervals &gt;5 days up to a maximum daily dose of 6 mg.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Dystonic reactions:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Initial dose: <b>IM, IV, Oral:</b> 1 to 2 mg once.</p>
<p style="text-indent:-2em;margin-left:10em;">Subsequent doses: <b>Oral:</b> 1 to 2 mg 1 to 2 times daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Prevention, dystonic reactions:</b>
<b>Note: </b>May be useful for preventing acute dystonic reactions when administering drugs with increased risk of causing such reactions (eg, haloperidol, metoclopramide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7494570','lexi-content-ref-19955388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7494570','lexi-content-ref-19955388'])">Ref</a></span>); however, in general oral prophylactic use is not recommended to prevent antipsychotic-associated EPS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7997388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7997388'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM, IV:</b> 1 to 2 mg prior to administration of high-risk medication (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stroup.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stroup.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3f01595c-b615-45af-983e-0a196d0c3f4f">Parkinsonism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parkinsonism: IM, IV, Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Idiopathic parkinsonism:</i> Initial: 0.5 to 1 mg/day as a single dose at bedtime or in 2 to 4 divided doses. Titrate in 0.5 mg increments every 5 to 6 days based on response and tolerability. Usual dose: 1 to 2 mg/day (range: 0.5 to 6 mg/day) although some patients may need 4 to 6 mg/day; maximum: 6 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postencephalitic parkinsonism:</i> Initial: 2 mg/day as a single dose at bedtime or in 2 to 4 divided doses; a lower initial dose of 0.5 mg at bedtime may be considered in highly sensitive patients. Titrate in 0.5 mg increments every 5 to 6 days based on response and tolerability. Usual dose: 1 to 2 mg/day (range: 0.5 to 6 mg/day); maximum: 6 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Lower initial doses may be appropriate for older and thinner patients.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990622"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987955"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block arsc drugH1Div" id="F58000813"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Anticholinergic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Benztropine may cause anticholinergic effects, such as <b>blurred vision</b>, <b>constipation</b>, <b>mydriasis</b>, <b>paralytic ileus,</b>
<b>tachycardia</b>, <b>urinary retention</b>, and <b>xerostomia. </b>Anticholinergic effects may require dose reduction or treatment discontinuation. (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10952768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10952768'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; related to the pharmacologic action. Directly related to antagonism of muscarinic receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2661606']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2661606'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21596217']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21596217'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10952768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10952768'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use with medications with anticholinergic properties (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3708528']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3708528'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyperthermia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Benztropine can cause anhidrosis, which may result in life-threatening <b>hyperthermia</b> or <b>heatstroke</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18025545','lexi-content-ref-33758045','lexi-content-ref-6831343']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18025545','lexi-content-ref-33758045','lexi-content-ref-6831343'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; related to the pharmacologic action. Antagonism of central and peripheral muscarinic receptors results in increased heat production due to increased muscle activity and impaired sweat gland function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23261898']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23261898'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Environmental heat exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18025545','lexi-content-ref-6831343']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18025545','lexi-content-ref-6831343'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use with other anticholinergic medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18025545','lexi-content-ref-33758045']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18025545','lexi-content-ref-33758045'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Existing sweating disorder</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Psychiatric effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Benztropine may cause psychiatric effects, including <b>confusion, depression, </b>delirium, <b>psychotic symptoms, memory impairment</b>, and <b>nervousness</b>. Psychiatric effects are reversible with discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2661606','lexi-content-ref-7263143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2661606','lexi-content-ref-7263143'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; related to pharmacologic action. Related to antagonism of muscarinic receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2885890']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2885890'])">Ref</a></span>). Dopaminergic and noradrenergic activity may also contribute to effects of CNS activation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24102938']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24102938'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; hallucinations and psychosis have been reported as early as 45 minutes and up to several months following treatment initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4746144','lexi-content-ref-6655530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4746144','lexi-content-ref-6655530'])">Ref</a></span>). Effects on memory and cognition have been reported within 4 days of treatment initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2661606','lexi-content-ref-2887553']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2661606','lexi-content-ref-2887553'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4746144']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4746144'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (&gt;60 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2887553','lexi-content-ref-6655530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2887553','lexi-content-ref-6655530'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26383155']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26383155'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F140187"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Heatstroke (Stadnyk 1983)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation, nausea, paralytic ileus (Kwiatkowski 2011), vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysuria, urinary retention</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression, hyperthermia (Manivannan 2021), lethargy, nervousness, numbness of fingers, psychotic symptoms, toxic psychosis (including confusion, disorientation, memory impairment, visual hallucination) (Grace 1997)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, mydriasis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever, hyperpyrexia (Green 2001)</p></div>
<div class="block coi drugH1Div" id="F140200"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to benztropine mesylate or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">Children &lt;3 years of age (due to atropine-like adverse effects including severe anhidrosis and fatal hyperthermia) and should be used cautiously in older children.</p></div>
<div class="block war drugH1Div" id="F140184"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Muscle weakness: When given in large doses or to susceptible patients, may cause weakness and inability to move particular muscle groups.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with tachycardia.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI obstruction: Use with caution in patients with obstructive disease of the GI tract (eg, pyloric or duodenal obstruction).</p>
<p style="text-indent:-2em;margin-left:4em;">• Glaucoma: Use with caution in patients with glaucoma; avoid use in angle-closure glaucoma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture or retention.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Use with caution in children &gt;3 years of age due to its anticholinergic effects; dose has not been established. Use is contraindicated in children &lt;3 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Tardive dyskinesia: Not recommended for use in patients with tardive dyskinesia; benztropine does not relieve symptoms of tardive dyskinesia and may potentially exacerbate symptoms.</p></div>
<div class="block foc drugH1Div" id="F140194"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as mesylate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cogentin: 1 mg/mL (2 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as mesylate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as mesylate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg, 1 mg, 2 mg</p></div>
<div class="block geq drugH1Div" id="F140180"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F140203"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Benztropine Mesylate Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per mL): $27.00 - $37.50</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Benztropine Mesylate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $0.20 - $0.53</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $0.23 - $0.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $0.25 - $0.68</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866049"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as mesylate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as mesylate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg, 2 mg [DSC]</p></div>
<div class="block admp drugH1Div" id="F52612296"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May be given with or without food; administration with food may decrease GI upset.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV route should be reserved for situations when oral or IM are not appropriate. Manufacturer's labeling states there is no difference in onset of effect after IV or IM injection and therefore there is usually no need to use the IV route. No specific instructions on administering benztropine IV are provided in the labeling. The IV route has been reported in the literature in adults (slow IV push when reported), although specific instructions are lacking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15321589','lexi-content-ref-9768805','lexi-content-ref-7862817','lexi-content-ref-11973196']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15321589','lexi-content-ref-9768805','lexi-content-ref-7862817','lexi-content-ref-11973196'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F13244987"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer with or without food.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Injectable:</b> Administer IM or IV if oral route is unacceptable. Manufacturer’s labeling states there is no difference in onset of effect after IV or IM injection and therefore there is usually no need to use the IV route. No specific instructions on administering benztropine IV are provided in the labeling. The IV route has been reported in the literature (slow IV push when reported), although specific instructions are lacking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15321589','lexi-content-ref-9768805','lexi-content-ref-7862817','lexi-content-ref-11973196']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15321589','lexi-content-ref-9768805','lexi-content-ref-7862817','lexi-content-ref-11973196'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F25564358"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F).</p></div>
<div class="block usep drugH1Div" id="F53565632"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Adjunctive treatment of parkinsonism; control of extrapyramidal disorders (except tardive dyskinesia) (All indications: FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F140235"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Benztropine may be confused with bromocriptine</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Benztropine (oral) is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older due to its highly anticholinergic properties. It is not recommended for the prevention or treatment of extrapyramidal symptoms with antipsychotics. In the treatment of Parkinson disease, more effective agents are available (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F140223"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2D6 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F140189"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ioflupane I 123: Benztropine may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: Benztropine may enhance the adverse/toxic effect of Lisuride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: Anticholinergic Agents may enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F13276950"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Paralytic ileus (which resolved rapidly) was reported in two newborns exposed to a combination of benztropine and chlorpromazine during the second and third trimesters and the last 6 weeks of pregnancy, respectively (Falterman 1980).</p></div>
<div class="block mopp drugH1Div" id="F53565634"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Heart rate; monitor for anticholinergic effects (baseline and as clinically indicated).</p></div>
<div class="block pha drugH1Div" id="F140183"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Possesses both anticholinergic and antihistaminic effects. <i>In vitro</i> anticholinergic activity approximates that of atropine; <i>in vivo</i> it is only about half as active as atropine. Animal data suggest its antihistaminic activity and duration of action approach that of pyrilamine maleate.</p></div>
<div class="block phk drugH1Div" id="F140199"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">IM, IV: Within a few minutes; there is no significant difference between onset of effect after intravenous or intramuscular injection</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Oral: Within 1 hour</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic (N-oxidation, N-dealkylation, and ring hydroxylation) (from animal studies only) (Brocks 1999)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, plasma: Oral: 7 hours (Brocks 1999)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038537"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Cogentin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Benztrop | Cogentin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo benztropine</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cogentinol</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cogentin | Cogintol</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Akitan | Cogentin</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cogentin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo benztropine | Cogentin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Cogentin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Cogentin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Benzpin | Benzpine | Benztropine | Myungin benztropine mesylate | Wi benztropine</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo benztropine | Cogentin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cogentin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Benztrop | Cogentin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Cogentin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Benztropine mesylate | Cogentin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cogentin</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Cogintol</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Cogentin | Pms benztropine</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cogentin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo-Bentropine | Cogentin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Cogentin | Phatropine</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cogentin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4746144">
<a name="4746144"></a>Ananth JV, Jain RC. Benztropine psychosis. <i>Can Psychiatr Assoc J</i>. 1973;18(5):409-414. doi:10.1177/070674377301800511<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/4746144/pubmed" id="4746144" target="_blank">4746144</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4424791">
<a name="4424791"></a>Bellman MH. Treatment of phenothiazine drug intoxication with benztropine. <i>Arch Dis Child</i>.1974;49(8):664-665.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/4424791/pubmed" id="4424791" target="_blank">4424791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Akorn.1">
<a name="Akorn.1"></a>Benztropine injection [prescribing information]. Lake Forest, IL: Akorn, Inc.; November 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Major.1">
<a name="Major.1"></a>Benztropine tablets [prescribing information]. Livonia, MI: Major Pharmaceuticals; October 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cipla.1">
<a name="Cipla.1"></a>Benztropine Mesylate (USP tablets) [prescribing information]. Warren, NJ: Cipla USA, Inc; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10952768">
<a name="10952768"></a>Brocks DR. Anticholinergic drugs used in Parkinson's disease: An overlooked class of drugs from a pharmacokinetic perspective. <i>J Pharm Pharm Sci</i>. 1999;2(2):39-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/10952768/pubmed" id="10952768" target="_blank">10952768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Congentin.1">
<a name="Congentin.1"></a>Cogentin (benztropine) injection [prescribing information]. Lake Forest, IL: Akorn, Inc; September 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22651987">
<a name="22651987"></a>Desmarais JE, Beauclair L, Margolese HC. Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment? <i>J Psychopharmacol</i>. 2012;26(9):1167-1174. doi:10.1177/0269881112447988<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/22651987/pubmed" id="22651987" target="_blank">22651987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15321589">
<a name="15321589"></a>Duncan MA, Nikolov NM, and O'Kelly B. Acute chorea due to ondansetron in an obstetric patient. <i>Int J Obstet Anesth</i>. 2001;10(4):309-311.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/15321589/pubmed" id="15321589" target="_blank">15321589</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-740090">
<a name="740090"></a>Falterman CG, Richardson CJ. Small left colon syndrome associated with maternal ingestion of psychotropic drugs. <i>J Pediatr</i>. 1980;97(2):308-310.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/740090/pubmed" id="740090" target="_blank">740090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20494268">
<a name="20494268"></a>Findling RL, Johnson JL, McClellan J, et al. Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. <i>J Am Acad Child Adolesc Psychiatry</i>. 2010;49(6):583-594<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/20494268/pubmed" id="20494268" target="_blank">20494268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2661606">
<a name="2661606"></a>Gelenberg AJ, Van Putten T, Lavori PW, et al. Anticholinergic effects on memory: benztropine versus amantadine. <i>J Clin Psychopharmacol</i>. 1989;9(3):180-185.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/2661606/pubmed" id="2661606" target="_blank">2661606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9359932">
<a name="9359932"></a>Grace RF. Benztropine abuse and overdose--case report and review. <i>Adverse Drug React Toxicol Rev</i>. 1997;16(2):103-112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/9359932/pubmed" id="9359932" target="_blank">9359932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11394759">
<a name="11394759"></a>Green H, Gilbert J, James R, Byard RW. An analysis of factors contributing to a series of deaths caused by exposure to high environmental temperatures. <i>Am J Forensic Med Pathol</i>. 2001;22(2):196-199. doi:10.1097/00000433-200106000-00018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/11394759/pubmed" id="11394759" target="_blank">11394759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10411778">
<a name="10411778"></a>Habre W, Wilson D, Johnson CM. Extrapyramidal side-effects from droperidol mixed with morphine for patient-controlled analgesia in two children. <i>Paediatr Anaesth</i>. 1999;9(4):362-364.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/10411778/pubmed" id="10411778" target="_blank">10411778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2885890">
<a name="2885890"></a>Hitri A, Craft RB, Fallon J, Sethi R, Sinha D. Serum neuroleptic and anticholinergic activity in relationship to cognitive toxicity of antiparkinsonian agents in schizophrenic patients. <i>Psychopharmacol Bull</i>. 1987;23(1):33-37.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/2885890/pubmed" id="2885890" target="_blank">2885890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9359953">
<a name="9359953"></a>Holloman LC, Marder SR. Management of acute extrapyramidal effects induced by antipsychotic drugs. <i>Am J Health Syst Pharm</i>. 1997;54(21):2461-2477.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/9359953/pubmed" id="9359953" target="_blank">9359953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7492048">
<a name="7492048"></a>Joseph MM, King WD. Dystonic reaction following recommended use of a cold syrup. <i>Ann Emerg Med</i>. 1995;26(6):749-751.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/7492048/pubmed" id="7492048" target="_blank">7492048</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7494570">
<a name="7494570"></a>Kane JM. Schizophrenia. <i>N Engl J Med.</i> 1996;334(1):34-41. doi: 10.1056/NEJM199601043340109.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/7494570/pubmed" id="7494570" target="_blank">7494570</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18025545">
<a name="18025545"></a>Kao RL, Kelly LM. Fatal exertional heat stroke in a patient receiving zuclopenthixol, quetiapine and benztropine. <i>Can J Clin Pharmacol</i>. 2007;14(3):e322-e325.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/18025545/pubmed" id="18025545" target="_blank">18025545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32867516">
<a name="32867516"></a>Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. <i>Am J Psychiatry</i>. 2020;177(9):868-872. doi:10.1176/appi.ajp.2020.177901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/32867516/pubmed" id="32867516" target="_blank">32867516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19955388">
<a name="19955388"></a>Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB; Schizophrenia Patient Outcomes Research Team (PORT). The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. <i>Schizophr Bull</i>. 2010;36(1):94-103. doi: 10.1093/schbul/sbp130.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/19955388/pubmed" id="19955388" target="_blank">19955388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21596217">
<a name="21596217"></a>Kwiatkowski M, Denka ZD, White CC. Paralytic ileus requiring hospitalization secondary to high-dose antipsychotic polypharmacy and benztropine. <i>Gen Hosp Psychiatry</i>. 2011;33(2):200.e5-200.e7. doi:10.1016/j.genhosppsych.2010.10.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/21596217/pubmed" id="21596217" target="_blank">21596217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9768805">
<a name="9768805"></a>Lydon AM and Boylan JF. Reversibility of parkinsonism-induced acute upper airway obstruction by benztropine therapy. <i>Anesth Analg</i>. 1998;87(4):975-976.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/9768805/pubmed" id="9768805" target="_blank">9768805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33758045">
<a name="33758045"></a>Manivannan A, Kabbani D, Levine D. Use of multiple anticholinergic medications can predispose patients to severe non-exertional hyperthermia. <i>BMJ Case Rep</i>. 2021;14(3):e239873. doi:10.1136/bcr-2020-239873<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/33758045/pubmed" id="33758045" target="_blank">33758045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17667476">
<a name="17667476"></a>McClellan J, Sikich L, Findling RL, et al. Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007;46(8):969-978.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/17667476/pubmed" id="17667476" target="_blank">17667476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23972700">
<a name="23972700"></a>McClellan J, Stock S; American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. <i>J Am Acad Child Adolesc Psychiatry</i>. 2013;52(9):976-990. doi:10.1016/j.jaac.2013.02.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/23972700/pubmed" id="23972700" target="_blank">23972700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2887553">
<a name="2887553"></a>McEvoy JP. A double-blind crossover comparison of antiparkinson drug therapy: amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function. <i>J Clin Psychiatry</i>. 1987;48 Suppl:20-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/2887553/pubmed" id="2887553" target="_blank">2887553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6138370">
<a name="6138370"></a>McEvoy JP, “The Clinical Use of Anticholinergic Drugs as Treatment for Extrapyramidal Side Effects of Neuroleptic Drugs,” <i>J Clin Psychopharmacol</i>, 1983, 3(5):288-302.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/6138370/pubmed" id="6138370" target="_blank">6138370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3708528">
<a name="3708528"></a>Moreau A, Jones BD, Banno V. Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.<i> Can J Psychiatry</i>. 1986;31(4):339-41. doi:10.1177/070674378603100411<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/3708528/pubmed" id="3708528" target="_blank">3708528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23261898">
<a name="23261898"></a>Musselman ME, Saely S. Diagnosis and treatment of drug-induced hyperthermia. <i>Am J Health Syst Pharm</i>. 2013;70(1):34-42. doi:10.2146/ajhp110543<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/23261898/pubmed" id="23261898" target="_blank">23261898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nelson.1">
<a name="Nelson.1"></a>Nelson WE, Behrman RE, Arvin AM, Kliegman RM, eds. <i>Nelson Textbook of Pediatrics</i>. 15th ed. Philadelphia, PA: WB Saunders Company; 1996: 2058-2078.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24102938">
<a name="24102938"></a>Ogino S, Miyamoto S, Miyake N, Yamaguchi N. Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function. <i>Psychiatry Clin Neurosci</i>. 2014;68(1):37-49. doi:10.1111/pcn.12088<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/24102938/pubmed" id="24102938" target="_blank">24102938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33813918">
<a name="33813918"></a>Pagliaro A, Mattio B, Paulson N, Fromm C, Vidal J. Unprovoked dystonic reaction in a child taking long-term methylphenidate. <i>J Pharm Pract</i>. 2022;35(5):796-799. doi:10.1177/0897190021999781<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/33813918/pubmed" id="33813918" target="_blank">33813918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pendopharm.2">
<a name="Pendopharm.2"></a>pdp-Benztropine (benztropine) [prescribing information]. Montréal, Québec, Canada: Pendopharm; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7862817">
<a name="7862817"></a>Sachdev P and Loneragan C. Intravenous benztropine and propranolol challenges in tardive akathisia. <i>Psychopharmacology (Berl)</i>. 1993;113 (1):119-122.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/7862817/pubmed" id="7862817" target="_blank">7862817</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11973196">
<a name="11973196"></a>Schramm BM and Orser BA. Dystonic reaction to propofol attenuated by benztropine (Cogentin). <i>Anesth Analg</i>. 2002;94(5):1237-1240.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/11973196/pubmed" id="11973196" target="_blank">11973196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6831343">
<a name="6831343"></a>Stadnyk AN, Glezos JD. Drug-induced heat stroke. <i>Can Med Assoc J</i>. 1983;128(8):957-959.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/6831343/pubmed" id="6831343" target="_blank">6831343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stroup.1">
<a name="Stroup.1"></a>Stroup TS, Marder S. Schizophrenia in adults: maintenance therapy and side effect management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 28, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7263143">
<a name="7263143"></a>Syndulko K, Gilden ER, Hansch EC, Potvin AR, Tourtellotte WW, Potvin JH. Decreased verbal memory associated with anticholinergic treatment in Parkinson's disease patients. <i>Int J Neurosci</i>. 1981;14(1-2):61-66. doi:10.3109/00207458108985816<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/7263143/pubmed" id="7263143" target="_blank">7263143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11869410">
<a name="11869410"></a>Teoh L, Allen H, Kowalenko N. Drug-induced extrapyramidal reactions. <i>J Paediatr Child Health</i>. 2002;38(1):95-97.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/11869410/pubmed" id="11869410" target="_blank">11869410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26383155">
<a name="26383155"></a>Thornton SL, Farnaes L, Minns A. Prolonged antimuscarinic delirium in a child due to benztropine exposure treated with multiple doses of physostigmine. <i>Pediatr Emerg Care</i>. 2016;32(4):243-245. doi:10.1097/PEC.0000000000000503<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/26383155/pubmed" id="26383155" target="_blank">26383155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7997388">
<a name="7997388"></a>Tonda ME, Guthrie SK. Treatment of acute neuroleptic-induced movement disorders. <i>Pharmacotherapy</i>. 1994;14(5):543-560.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/7997388/pubmed" id="7997388" target="_blank">7997388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6655530">
<a name="6655530"></a>Wilcox JA. Psychoactive properties of benztropine and trihexyphenidyl. <i>J Psychoactive Drugs</i>. 1983;15(4):319-321. doi:10.1080/02791072.1983.10471970<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benztropine-benzatropine-pediatric-drug-information/abstract-text/6655530/pubmed" id="6655530" target="_blank">6655530</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13024 Version 446.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
